irix-8k_20190723.DOCX.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

July 23, 2019

(Date of Report (date of earliest event reported))

 

IRIDEX CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

0-27598

77-0210467

(State or other jurisdiction

of incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification Number)

1212 Terra Bella Avenue

Mountain View, California 94043

(Address of principal executive offices, including zip code)

(650) 940-4700

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of Class

 

Trading

Symbol

 

Name of Exchange on Which Registered

Common Stock, par value $0.01 per share

 

IRIX

 

Nasdaq Global Market

 

 

 

 

 

-1-


 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. 

 

Committee Assignments

 

On July 23, 2019, the Board of Directors modified the composition of the Audit Committee, Compensation Committee, and Nominating and Governance Committee of the Company to consist of the following directors:

 

 

Audit Committee: Kenneth E. Ludlum (Chair), Scott Shuda, Robert Grove, and Robert Gunst.

 

Compensation Committee: Maria Sainz (Chair), Robert Grove, Kenneth E. Ludlum, and Scott Shuda.

 

Nominating and Governance Committee: Ruediger Naumann-Etienne, Ph.D (Chair), Maria Sainz, and Robert Grove.

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

The 2019 Annual Meeting of Stockholders (the Annual Meeting) of Iridex Corporation (the Company) was held on July 23, 2019, at the Company’s headquarters located at 1212 Terra Bella Avenue, Mountain View, CA 94043. Present at the Annual Meeting in person or by proxy were holders of 12,652,927 shares of the Companys common stock, constituting a quorum for the transaction of business. The proposals voted upon at the meeting and the vote with respect to each such matter are as set forth below:

Proposal 1: Election of Directors.

 

Nominee

For

Against

Withheld

Broker Non-Votes*

David I. Bruce

7,970,711

487,395

191,500

4,003,321

Ruediger Naumann-Etienne, Ph.D

7,970,911

558,895

119,800

4,003,321

Robert Grove

7,971,711

558,395

119,500

4,003,321

Kenneth E. Ludlum

8,383,749

146,357

119,500

4,003,321

Scott Shuda

8,119,362

80,506

449,738

4,003,321

Maria Sainz

7,930,186

599,620

119,800

4,003,321

Robert Gunst

8,382,949

146,857

119,800

4,003,321

*Broker non-votes did not affect the outcome of the election.

Based on the votes set forth above, each director nominee was duly elected to serve until the 2020 Annual Meeting of Stockholders or until his or her respective successor is duly elected and qualified or until his or her earlier death, resignation or removal.

 

Proposal 2: To ratify the appointment of BPM LLP as the Companys independent registered public accounting firm for the fiscal year ending December 28, 2019.

 

For

Against

Abstain

Broker Non-Votes

12,518,694

12,186

122,047

0

 

Based on the votes set forth above, the stockholders ratified the appointment of BPM LLP as the Companys independent registered public accounting firm for the fiscal year ending December 28, 2019.

 

 

Proposal 3: Advisory Non-Binding Vote on Named Executive Officer Compensation.

 

For

Against

Abstain

Broker Non-Votes

6,640,061

1,991,753

17,792

4,003,321

The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.

 

-2-


 

 

Proposal 4: Advisory Non-Binding Vote on Frequency of Future Advisory Votes to Approve Named Executive Officer Compensation.

 

One Year

Two Years

Three Years

Abstain

Broker Non-Votes

7,203,468

100

188,929

1,257,109

4,003,321

In accordance with the recommendation of the Board of Directors, the Company’s stockholders approved, on an advisory basis, one year as the frequency for holding future advisory votes to approve the compensation of the Company’s named executive officers.  In light of such approval, the Company intends to hold an advisory vote on the compensation of the Company’s named executive officers on an annual basis until the next required vote on the frequency of holding an advisory vote to approve named executive officer compensation.

 

Proposal 5: Approval of the Amended and Restated 2008 Equity Incentive Plan.

 

For

Against

Abstain

Broker Non-Votes

6,905,463

1,716,880

27,263

4,003,321

The stockholders approved the Amended and Restated 2008 Equity Inventive Plan.

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

IRIDEX CORPORATION

 

 

By:

 

/s/ David I. Bruce

 

 

David I. Bruce

President and Chief Executive Officer

Date: July 25, 2019

 

 

-3-